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Summary 
The receptors that mediate monocyte adhesion to cytokine-stimulated endothelial monolayers 
were assessed using a nonstatic (rotating) cell-attachment assay. In this system, leukocyte adhesion 
molecule-1 (LAM-1) (L-sdectin) mediated a major portion (87  _+  15% at 37~  of monocyte 
attachment to activated endothelium, mAb blocking of endothelial leukocyte adhesion molecule.1 
(41% inhibition),  CD18 (36%), and vascular cell adhesion molecule.1 (25%) function had lesser 
effects on attachment. These results suggest that LAM-1 may serve an important role in monocyte 
attachment  to endothelium  at  sites  of inflammation. 
T 
he initial event in the emigration of monocytes from the 
blood stream into inflamed tissues is adhesion to the en- 
dothelial  blood  vessd  lining  (1).  Monocyte  adhesion  to 
cytokine-activated cultured human umbilical vein endothelial 
ceUs (HUVEC)  is partially  inhibited  by mAb binding  to 
CD18,  CDllb,  CDllc,  intercellular  adhesion  molecule-1 
(ICAM-1),  endothdial-leukoc~ adhesion molecule-1 (ELAM-1) 
(E-sdectin), and vascular cell adhesion molectfle.1 (VCAM- 
1) (inducible cell adhesion molecule-110 [INCAM-110]),  or com- 
binations of these mAbs (2-4). However, these in vitro assays 
were carried out under static conditions, while monocyte in- 
teractions with endothelium in vivo occur under conditions 
of blood flow. When examined under nonstatic (stirred) con- 
ditions in vitro, monocyte adherence to endothelial cells ap- 
peared  to involve both  CD18-independent  and unknown, 
CD18-independent  mechanisms (5). In the present study, a 
nonstatic (rotation) assay (6) was used to examine the adhe- 
sion molecules involved in the attachment of peripheral blood 
monocytes to cytokine-activated HUVEC. 
Materials  and Methods 
Monocytes.  Blood monocytes were isohted by density gradient 
centrifugation  followed by counterflow centrifugation  ehtriation 
as described (7). Preparations contained 87  _+  5% monocytes as 
determined by light scatter, Wright-Giemsa  stain and surface an- 
tigen analysis. Monocytes  (5  x  10  s) were incubated  in 1 ml of 
RPMI 1640 (Gibco, Gaithersburg,  MD) containing  1% human 
serum albumin alone or containing PMA (100 ng/ml; Sigma Chem- 
ical Co., St. Louis, MO), GM-CSF (Genetics Institute, Cambridge, 
MA; 20 rig/m1; -2  x  109 U/rag), A23187 (3 ~M; Sigma Chem- 
ical Co.), TNF-cx (200 U/ml; Genzyme Corp., Cambridge, MA), 
or LPS (1/zg/ml; Escherichia coli strain 0111:B4; Sigma Chemical 
Co.) for 20 rain at 37~  with gentle mixing to prevent cell attach- 
ment. All buffers and reagents contained <1 ng/ml of endotoxin. 
mAE  The anti-leukocyte adhesion molecule-1 (LAM-1) mAb 
(all IgG1) (8), anti-CD18 (H52, IgG1) (9), and anti-VCAM-1 mAb 
(HAE-2, IgG1) (6) were used as diluted ascites fluid (1:100). The 
anti-ELAM-1 mAb (H18/7; IgG2a) (10) and anti-HLA class I mAb 
(W6/32,  IgG2a)  were  used  as  purified  F(ab'2) fragments  (25 
~,g/ml). 
Endothelial-leukocyte Attachment Assay.  Assays  were as described 
(6). Briefly HUVEC (passage 2 to 3) were grown to confluence 
on gehtin-coated glass slides, stimulated with TNF-oe (100 U/nil; 
6 h), washed, and incubated for 15 min with media (RPM11640/5% 
FCS) alone or containing  mAb. In parallel, monocytes (4  x  106) 
were incubated in media (100 Ill, 10 rain, 4~  COntaining monocyte- 
and/or endothelial-directed mAb before addition to the endothelial 
monohyers that were kept static or rotated at 64 rpm. After 8 rain 
at 37~  or 30 rain at 4~  the medium was gently removed and 
the slides were fixed overnight.  The number of adherent  leuko- 
cytes in 4-12 microscopic fields (0.09 mm  z) were counted and the 
results were extn~sed as means + SD. Inhibition of monocyte adhe- 
sion was calculated using the level of attachment  to unstimuhted 
HUVEC as the baseline and the level of monocyte attachment  to 
stimulated HUVEC obtained in the presence of control mAb as 
the maximal value. 
Stat/stis.  Significance  was determined using the paired Student's 
t test. 
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Figure 1.  Monocyte expression of LAM-1. Monocytes were isolated by 
dutriation, kept at 4~  or incubated for 20 min at 37~  in media alone 
or with various activating agents.  LAM-1 expression was then assessed 
by indirect immunofluor~-~,,encr staining using the anti-LAMl-1 mAb with 
flow cytometry analysis as described (16). The fluorescence intensity (four 
decade log scale) of cells stained with an isotype-matched  unreactive con- 
trol mAb is shown as a thin line (4~  panel). 
Results 
Monocyte Expression of  LAM-1.  Isolation ofmonocytes by 
elutriation only resulted in a 40% loss of cell surface LAM-1 
expression when compared with monocytes in whole blood 
by indirect immunofluorescence anal)sis. In three experiments, 
incubation of monocytes at 37~  for 20 min resulted  in a 
further 53  +  10% loss of LAM-1 compared with cells kept 
at 4~  for 20 min (Fig. 1). Treatment of the ceils with GM- 
CSF, TNF-o~,  LPS, PMA,  and calcium ionophore, resulted 
in LAM-1 loss of 73  +  10%,  63  _+  11%, 80  _+  5%, 94  _+ 
1%, and 89  +  7%, respectively. Therefore, after elutriation, 
the monocytes responded  to inflammatory stimuli and shed 
LAM-1. 
LAM-1  Mediates Monocyte Attachment to Activated Endo- 
theliura.  Monocyte binding to endothdium under static and 
rotating  conditions  was  examined  to  determine  whether 
different receptors function during the different phases of adhe- 
sion. Under static conditions at 37~  monocytes avidly bound 
(479  +  27/fidd) to unactivated  HUVEC monolayers  (Fig. 
2).  Although few monocytes (79  +  4) attached to the en- 
dothdium under rotating conditions, a significant  increase 
in monocyte attachment  occurred under both static (676  _+ 
Figure 3.  LAM-1 primarily mediates monocyte attachment to endothelial 
cells under nonstatic  conditions.  Assays were carried  out at 37~  for 8 
min (/1), and 4~  for 30 rain (B). Confluent endothelial monolayers were 
cultured with medium (shaded bars) or with TNF-o~ (filled bars). Mono- 
cytes and endothelial cells were treated with medium or mAb reactive with 
HLA  class  I  (W6/32),  LAM-1  (anti-LAM1-3),  VCAM-1  (HAE-2), 
ELAM-1 (H18/7), and CD18 (H52) before and during the assays. Results 
are representative  of three experiments. 
36)  and rotating  (671  _+  32) conditions  when  endothelial 
cells were cultured with TNF-ol for 6 h. Treatment of mono- 
cytes with an anti-HLA class I mAb had no effect on attach- 
ment (Fig. 2). In contrast, treatment of monocytes with anti- 
LAM1-3 mAb inhibited a significant proportion (87  _+  15% 
inhibition,  n  =  3, p  <0.005) of cytokine-induced adhesion 
Table  1.  Inhibition  of Monocyte  Binding  to Activated 
HUVEC  at  4~ 
mAb  No.  bound/field  Percent  inhibition 
Figure 2.  LAM-1 mediates monocyte attachment  to endothelium under 
nonstatic  conditions.  Endothelial  monolayers  were cultured in medium 
or TNF-~ and the monocytes  were incubated  with anti-HLA class I or 
anti-LAM1-3 mAb before and during the assay at 37~  During the at- 
tachment assay, the slides were kept static (shaded bars) or were rotated 
(filled bars) at 64 rpm.  Results  are representative  of three  experiments. 
Medium  725  +  56 
LAMI-1  421  +  52  42** 
LAM1-3  230  _+  50  68  s 
LAM1-4  213  +  68  71 s 
LAM1-5  655  _+  52  10 
LAM1-6  356  +  38  51s 
LAM1-7  323  _+  45  55  s 
LAMI-10  613  +  40  15 
LAMl-11  709  +  56  2 
* Statistical  significance 
* p  <0.01. 
s p  <0.005. 
of inhibition. 
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to activated  endothelium in static assays  (Fig. 2). When viewed 
by phase contrast microscopy, adherent monocytes rapidly 
underwent shape change at 37~  and spread on the activated 
endothelium. Although the anti-LAM1-3 mAb blocked most 
monocyte attachment, it failed to inhibit spreading of the 
adherent monocytes, suggesting that different adhesion mol- 
ecules mediated these distinct events. Treatment of mono- 
cytes with PMA as in Fig. 1, which promotes loss of LAM-1 
with concomitant activation  of CD18,  inhibited 89%  of 
monocyte attachment to TNF-activated endothelium under 
nonstatic conditions (data not shown). However, lack of at- 
tachment may not be sdely due to loss of  LAM-1 since mono- 
cyte activation in general may cause decreased  attachment with 
LAM-1 loss serving as a marker for this event. 
LAM-I  is the Principal Adhesion Receptor  for Monocyte At- 
tachment to Activated Endothelium under Nonstatic Conditions.  In 
three experiments,  antibody binding to VCAM-1 inhibited 
cytokine-induced increases in monocyte adhesion by 25  _+ 
1%  (p  <0.025),  ELAM-1  mAb inhibited 41  _+  16%  (p 
<0.05), and CD18 mAb inhibited 36 _+ 3% ~ <0.01), indi- 
cating that these receptors participate in monocyte adhesion 
to activated endothelium at 37~  (Fig. 3 A). The combina- 
tion of anti-LAM1-3 mAb with either anti-ELAM-1 (97 _+ 
5% inhibition), anti-VCAM-1  (87  +  18%) or anti-CD18 
(88 +  18%) mAb only minimally  increased the level of inhi- 
bition of activation-dependent  adhesion (,o10%) indicating 
that these receptors may function in processes subsequent to 
LAM-l-mediated attachment. 
At 4~  where LAM-1 shedding is minimal and CD18- 
mediated adhesion is inactive, anti-LAM1-3 mAb inhibited 
a majority of monocyte attachment (60  +  8%, n  =  3, p 
<0.005)  to activated endothelium, while anti-ELAM-1 and 
anti-VCAM-1  mAb only inhibited by 19  _+  7% and 28  + 
7%,  respectively (Fig.  3 B).  Anti-HLA class I mAb was 
without effect (~4% inhibition).  The combination of anti- 
LAM1-3 mAb with anti-VCAM-1 or ELAM-1 mAb inhibited 
attachment by 63  +  1% and 56  +  1%, respectively, which 
was not significantly different from anti-LAM1-3 alone. The 
combination of anti-LAM1-3,  anti-ELAM-1, and VCAM-1 
mAb inhibited attachment by 83  _+  12%. At 4~  the at- 
tached monocytes remained spherical and did not spread on 
the activated endothelium. However, these assays were car- 
ried out for 30 min since the cellular activation-dependent 
change of LAM-1 affinity for ligand (11) appeared to result 
in a temperature-dependent decrease in the attachment of 
monocytes. Nonetheless, under nonstatic conditions LAM-1 
was the principal adhesion mechanism that mediated mono- 
cyte attachment to cytokine-activated  endothelium. 
The Same Epitapes of LAM-1 Mediate Monocyte and Lym- 
phocyte Attachment to Endothelium.  mAb that identify spa- 
tiaUy and functionally distinct epitopes on LAM-1 (8) were 
used to identify the epitopes involved in monocyte attach- 
ment to endothelium. The anti-LAMl-1, -3, -4, -6, and -7 
mAb, which inhibit lymphocyte  binding to high endothelial 
venules and to stimulated HUVEC (6), also inhibited mono- 
cyte binding (Table 1). Anti-LAM-1 mAb (anti-LAM1-5, 
-10, and -11) that do not inhibit lymphocyte  attachment, did 
not inhibit  monocyte attachment. Thus, identical epitopes 
of LAM-1 mediate monocyte and lymphocyte attachment. 
Discussion 
Although multiple adhesion mechanisms have been im- 
plicated in monocyte  adhesion to endothelium, mAb binding 
to functional epitopes on LAM-1 (bselectin) inhibited a major 
portion of monocyte attachment to cytokine-activated en- 
dothelium under nonstatic conditions (Figs. 2 and 3). The 
finding that LAM-l-mediated binding was only detectable 
under nonstatic conditions,  suggests that LAM-1 serves as 
the primary receptor that initiates attachment of monocytes 
to  activated endothelium. Similarly, in vitro studies  have 
demonstrated that P-selectin mediates neutrophil rolling at 
physiologic flow rates (12), while other studies have demon- 
strated that LAM-1 mediates neutrophil rolling in vivo (13, 
14). VCAM-1, ELAM-1, and CD18 also participated in mono- 
cyte adhesion to activated endothelium, but their relative con- 
tributions were modest in this  assay system. LAM-1  also 
mediates lymphocyte  and neutrophil attachment to activated 
endothelium under nonstatic  conditions in vitro (6),  but 
LAM-1 contributes less to lymphocyte (56%) and neutro- 
phil (27%)  attachment when compared with the current 
results for monocyte attachment (87%). 
A central role for LAM-1 in monocyte attachment to acti- 
vated vascular endothelium in vivo may partially explain the 
selective recruitment of different leukocyte subsets during 
different phases of inflammation. Neutrophils accumulate very 
rapidly in acute inflammatory lesions whereas lymphocytes 
and monocytes  become the predominant cell type with more 
chronic inflammation.  In vitro,  expression of the LAM-1 
ligand on cytokine-activated endothelium is sustained (6), in 
contrast to ELAM-1 expression (10), and is similar to the 
pattern of  VCAM-1 and ICAM-1 expression (15). Thus, sus- 
tained expression of the LAM-1 ligand in combination with 
other adhesion molecules in vivo could induce preferential 
recruitment of monocytes and lymphocytes during late phases 
of inflammation. 
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